Bienaime Jean Jacques insider trades
Bienaime Jean Jacques has filed 68 Form 4s with the SEC that we hold, for Biomarin Pharmaceutical INC (BMRN) (Director), Immunome Inc. (IMNM) (Director), Keros Therapeutics, Inc. (KROS) (Director) and Incyte Corp (INCY) (Director), among 5 companies in all. Across all of them we count 24 purchases worth $1.4M and 54 sales worth $43.7M reported on Form 4. In the last 12 months: 19 purchases ($1.1M) and 2 sales ($203.8K). The largest single trade was a sale of 24,439 shares of Biomarin Pharmaceutical INC worth $2.3M, dated 2023-05-11. The first filing on our record is dated 2021-10-22 and the latest 2026-09-28.
Biomarin Pharmaceutical INC (BMRN)
Director · 39 filings · 52 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-12-01 | S, sale reported on Form 4 | 1,500 | $130.8K | 2021-12-02 |
| 2021-12-15 | S, sale reported on Form 4 | 6,000 | $496.3K | 2021-12-17 |
| 2021-12-16 | S, sale reported on Form 4 | 6,000 | $508.1K | 2021-12-17 |
| 2022-01-12 | S, sale reported on Form 4 | 5,000 | $445.0K | 2022-01-14 |
| 2022-01-13 | S, sale reported on Form 4 | 5,000 | $439.3K | 2022-01-14 |
| 2022-03-10 | S, sale reported on Form 4 | 15,000 | $1.2M | 2022-03-14 |
| 2022-03-11 | S, sale reported on Form 4 | 15,000 | $1.2M | 2022-03-14 |
| 2022-04-14 | S, sale reported on Form 4 | 10,000 | $836.6K | 2022-04-18 |
| 2022-04-18 | S, sale reported on Form 4 | 20,000 | $1.6M | 2022-04-20 |
| 2022-04-28 | S, sale reported on Form 4 | 20,000 | $1.7M | 2022-05-02 |
| 2022-04-29 | S, sale reported on Form 4 | 5,000 | $409.8K | 2022-05-02 |
| 2022-05-05 | S, sale reported on Form 4 | 10,000 | $841.4K | 2022-05-09 |
| 2022-05-06 | S, sale reported on Form 4 | 20,000 | $1.6M | 2022-05-09 |
| 2022-08-12 | S, sale reported on Form 4 | 4,000 | $379.0K | 2022-08-16 |
| 2022-08-15 | S, sale reported on Form 4 | 3,000 | $285.6K | 2022-08-16 |
| 2022-10-14 | S, sale reported on Form 4 | 4,000 | $359.6K | 2022-10-18 |
| 2022-10-31 | S, sale reported on Form 4 | 1,500 | $129.8K | 2022-11-01 |
| 2022-12-02 | S, sale reported on Form 4 | 471 | $49.0K | 2022-12-06 |
| 2022-12-02 | S, sale reported on Form 4 | 600 | $62.4K | 2022-12-06 |
| 2022-12-02 | S, sale reported on Form 4 | 260 | $27.0K | 2022-12-06 |
| 2022-12-02 | S, sale reported on Form 4 | 100 | $10.4K | 2022-12-06 |
| 2022-12-02 | S, sale reported on Form 4 | 69 | $7.2K | 2022-12-06 |
| 2022-12-13 | S, sale reported on Form 4 | 1,000 | $106.9K | 2022-12-15 |
| 2023-01-13 | S, sale reported on Form 4 | 10,000 | $1.1M | 2023-01-18 |
| 2023-01-17 | S, sale reported on Form 4 | 10,000 | $1.1M | 2023-01-18 |
| 2023-02-10 | S, sale reported on Form 4 | 15,000 | $1.7M | 2023-02-14 |
| 2023-02-13 | S, sale reported on Form 4 | 6,000 | $654.9K | 2023-02-14 |
| 2023-03-10 | S, sale reported on Form 4 | 15,000 | $1.4M | 2023-03-14 |
| 2023-03-13 | S, sale reported on Form 4 | 8,000 | $723.6K | 2023-03-14 |
| 2023-04-06 | S, sale reported on Form 4 | 10,000 | $961.3K | 2023-04-10 |
| 2023-04-10 | S, sale reported on Form 4 | 10,000 | $995.6K | 2023-04-12 |
| 2023-05-09 | S, sale reported on Form 4 | 13,626 | $1.3M | 2023-05-11 |
| 2023-05-09 | S, sale reported on Form 4 | 14,964 | $1.4M | 2023-05-11 |
| 2023-05-09 | S, sale reported on Form 4 | 1,410 | $135.2K | 2023-05-11 |
| 2023-05-10 | S, sale reported on Form 4 | 21,453 | $2.0M | 2023-05-11 |
| 2023-05-10 | S, sale reported on Form 4 | 8,547 | $814.9K | 2023-05-11 |
| 2023-05-11 | S, sale reported on Form 4 | 5,561 | $529.5K | 2023-05-15 |
| 2023-05-11 | S, sale reported on Form 4 | 24,439 | $2.3M | 2023-05-15 |
| 2023-08-07 | S, sale reported on Form 4 | 4,000 | $352.4K | 2023-08-09 |
| 2023-08-08 | S, sale reported on Form 4 | 6,000 | $529.7K | 2023-08-09 |
| 2023-12-21 | S, sale reported on Form 4 | 10,000 | $939.9K | 2023-12-22 |
| 2024-01-09 | S, sale reported on Form 4 | 10,000 | $981.9K | 2024-01-11 |
| 2024-01-10 | S, sale reported on Form 4 | 10,000 | $963.8K | 2024-01-11 |
| 2024-02-08 | S, sale reported on Form 4 | 15,000 | $1.3M | 2024-02-12 |
| 2024-02-09 | S, sale reported on Form 4 | 15,000 | $1.3M | 2024-02-12 |
| 2024-02-27 | S, sale reported on Form 4 | 1,000 | $90.3K | 2024-02-29 |
| 2024-03-05 | S, sale reported on Form 4 | 1,000 | $85.5K | 2024-03-07 |
| 2024-03-06 | S, sale reported on Form 4 | 1,000 | $86.7K | 2024-03-07 |
| 2024-04-11 | S, sale reported on Form 4 | 20,000 | $1.8M | 2024-04-15 |
| 2024-04-12 | S, sale reported on Form 4 | 20,000 | $1.8M | 2024-04-15 |
| 2024-05-09 | S, sale reported on Form 4 | 20,000 | $1.6M | 2024-05-13 |
| 2024-05-10 | S, sale reported on Form 4 | 20,000 | $1.6M | 2024-05-13 |
Immunome Inc. (IMNM)
Director · 12 filings · 13 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-05-21 | P, purchase reported on Form 4 | 2,000 | $27.1K | 2024-05-22 |
| 2024-08-16 | P, purchase reported on Form 4 | 7,000 | $97.6K | 2024-08-19 |
| 2025-03-24 | P, purchase reported on Form 4 | 7,000 | $57.5K | 2025-03-25 |
| 2025-03-25 | P, purchase reported on Form 4 | 7,800 | $60.7K | 2025-03-26 |
| 2025-06-03 | P, purchase reported on Form 4 | 5,000 | $46.9K | 2025-06-03 |
| 2026-03-10 | P, purchase reported on Form 4 | 1,000 | $22.1K | 2026-03-12 |
| 2026-03-11 | P, purchase reported on Form 4 | 1,000 | $21.6K | 2026-03-12 |
| 2026-05-15 | P, purchase reported on Form 4 | 5,000 | $103.5K | 2026-05-19 |
| 2026-06-05 | S, sale reported on Form 4 | 500 | $9.7K | 2026-06-09 |
| 2026-06-05 | S, sale reported on Form 4 | 10,000 | $194.1K | 2026-06-09 |
| 2026-06-05 | P, purchase reported on Form 4 | 6,000 | $116.9K | 2026-06-09 |
| 2026-06-05 | P, purchase reported on Form 4 | 3,500 | $68.1K | 2026-06-09 |
| 2026-06-05 | P, purchase reported on Form 4 | 1,000 | $19.3K | 2026-06-09 |
Keros Therapeutics, Inc. (KROS)
Director · 9 filings · 6 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-03-09 | P, purchase reported on Form 4 | 2,000 | $22.4K | 2026-03-11 |
| 2026-04-15 | P, purchase reported on Form 4 | 1,000 | $11.7K | 2026-04-17 |
| 2026-05-15 | P, purchase reported on Form 4 | 1,000 | $10.6K | 2026-05-19 |
| 2026-06-15 | P, purchase reported on Form 4 | 1,000 | $10.2K | 2026-06-17 |
| 2026-07-15 | P, purchase reported on Form 4 | 1,000 | $10.6K | 2026-07-17 |
| 2026-08-17 | P, purchase reported on Form 4 | 1,000 | $10.3K | 2026-08-19 |
Incyte Corp (INCY)
Director · 6 filings · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Ascendis Pharma A/S (ASND)
Director · 4 filings · 7 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-05-26 | P, purchase reported on Form 4 | 200 | $47.9K | 2026-05-27 |
| 2026-05-26 | P, purchase reported on Form 4 | 200 | $47.2K | 2026-05-27 |
| 2026-05-29 | P, purchase reported on Form 4 | 200 | $44.8K | 2026-06-01 |
| 2026-05-29 | P, purchase reported on Form 4 | 100 | $22.4K | 2026-06-01 |
| 2026-05-29 | P, purchase reported on Form 4 | 200 | $44.5K | 2026-06-01 |
| 2026-08-14 | P, purchase reported on Form 4 | 1,100 | $270.4K | 2026-08-18 |
| 2026-08-14 | P, purchase reported on Form 4 | 900 | $222.2K | 2026-08-18 |
Source
Counted from the Form 4 filings this reporting owner (SEC CIK 1221590) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms